MannKind closed 2025 on a high note, marked by milestones that reinforce our growth trajectory—including the acquisition of scPharmaceuticals and a record-setting fourth quarter surpassing $100 ...

Halozyme Therapeutics, Inc. today announced the Company entered into a global collaboration and exclusive license agreement ...

When these elements come together, a geriatric program transforms from an aspirational concept into a practical reality. The practice becomes not only a provider of medical services but also a trusted ...

Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...

Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics ...

We’ve all been there. You start feeling off, so you decide to Google your symptoms. Suddenly, WebMD has you convinced that ...

It’s important to be able to advocate for yourself when you visit the doctor. If you truly believe that there’s something ...

Fossilized footprints, preserved in gypsum mud that hardened over time, are estimated to be 23,000-21,000 years old. NPS / Alamy Ancient human footprints, preserved in a dry lakebed at White Sands ...

Skye is planning to initiate a Phase 2b clinical trial in obesity for nimacimab with ENHANZE in the middle of 2026. This study will also assess the combination of nimacimab and a GLP-1R agonist.

Something about a warm, flickering campfire draws in modern humans. Where did that uniquely human impulse come from? How did our ancestors learn to make fire? How long have they been making it?

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...